All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 PD-L1 < 1% PD-L1 > 1%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
breast cancer - triple negative, pembrolizumab based treatment vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-119 (all population), 2019 0.97 [0.82; 1.15]
KEYNOTE-119 (PDL1 CPS>1), 2019 0.86 [0.69; 1.07]
KEYNOTE-119 (PDL1 CPS>10), 2019 0.78 [0.57; 1.06]
KEYNOTE-355 (all population), 2020 0.89 [0.76; 1.05]
KEYNOTE-355 (CPS>1), 2020 0.86 [0.72; 1.03]
KEYNOTE-355 (CPS>10), 2020 0.73 [0.56; 0.96]
0.87 [0.80 ; 0.95 ] KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 2020 6 0% 3,027 low serious progression or deaths (PFS)detailed results KEYNOTE-119 (all population), 2019 1.60 [1.33; 1.92]
KEYNOTE-119 (PDL1 CPS>1), 2019 1.35 [1.08; 1.68]
KEYNOTE-119 (PDL1 CPS>10), 2019 1.14 [0.82; 1.59]
KEYNOTE-355 (all population), 2020 0.82 [0.69; 0.97]
KEYNOTE-355 (CPS>1), 2020 0.75 [0.62; 0.91]
KEYNOTE-355 (CPS>10), 2020 0.66 [0.50; 0.88]
1.00 [0.75 ; 1.34 ] KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 2020 6 91% 3,027 low not evaluable DCRdetailed results KEYNOTE-119 (all population), 2019 0.60 [0.39; 0.94]
0.60 [0.39 ; 0.94 ] KEYNOTE-119 (all population), 2019 1 0% 622 NA not evaluable objective responses (ORR)detailed results KEYNOTE-119 (all population), 2019 0.89 [0.53; 1.50]
KEYNOTE-119 (PDL1 CPS>1), 2019 1.35 [0.72; 2.54]
KEYNOTE-119 (PDL1 CPS>10), 2019 2.13 [0.90; 5.04]
KEYNOTE-355 (all population), 2020 0.24 [0.17; 0.33]
KEYNOTE-355 (CPS>1), 2020 1.28 [0.92; 1.80]
KEYNOTE-355 (CPS>10), 2020 1.62 [1.01; 2.60]
1.01 [0.47 ; 2.17 ] KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 2020 6 94% 3,027 low not evaluable AE (any grade)detailed results KEYNOTE-355 (all population), 2020 1.25 [0.41; 3.87]
1.25 [0.41 ; 3.87 ] KEYNOTE-355 (all population), 2020 1 0% 843 NA not evaluable AE (grade 3-4)detailed results KEYNOTE-355 (all population), 2020 1.26 [0.91; 1.76]
1.26 [0.91 ; 1.76 ] KEYNOTE-355 (all population), 2020 1 0% 843 NA not evaluable SAE (any grade)detailed results KEYNOTE-119 (all population), 2019 0.99 [0.66; 1.48]
0.99 [0.66 ; 1.48 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable TRAE (any grade)detailed results KEYNOTE-355 (all population), 2020 1.35 [0.68; 2.70]
1.35 [0.68 ; 2.70 ] KEYNOTE-355 (all population), 2020 1 0% 843 NA not evaluable TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.29 [0.19; 0.43]
KEYNOTE-355 (all population), 2020 1.06 [0.78; 1.44]
0.56 [0.16 ; 1.99 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020 2 96% 1,444 low not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.37; 2.41]
KEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58]
1.00 [0.41 ; 2.47 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020 2 0% 1,444 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-119 (all population), 2019 1.05 [0.42; 2.63]
1.05 [0.42 ; 2.63 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18]
0.94 [0.06 ; 15.18 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
0.47 [0.02 ; 14.11 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
1.89 [0.06 ; 56.64 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78]
KEYNOTE-355 (all population), 2020 0.83 [0.20; 3.51]
0.84 [0.22 ; 3.26 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020 2 0% 1,444 low not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.28 [0.08; 1.01]
KEYNOTE-355 (all population), 2020 1.15 [0.77; 1.71]
0.65 [0.17 ; 2.54 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020 2 76% 1,444 low not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.26 [0.28; 5.69]
1.26 [0.28 ; 5.69 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
KEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58]
1.04 [0.10 ; 10.27 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020 2 0% 1,444 low not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
0.47 [0.02 ; 14.11 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Cough TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
1.89 [0.06 ; 56.64 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
0.47 [0.02 ; 14.11 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18]
0.94 [0.06 ; 15.18 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.23 [0.05; 1.10]
0.23 [0.05 ; 1.10 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
1.89 [0.06 ; 56.64 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.19; 4.72]
KEYNOTE-355 (all population), 2020 1.15 [0.47; 2.82]
1.10 [0.50 ; 2.40 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020 2 0% 1,444 low not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.05 [0.00; 0.79]
0.05 [0.00 ; 0.79 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Headache TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
1.89 [0.06 ; 56.64 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78]
KEYNOTE-355 (all population), 2020 1.00 [0.03; 29.90]
0.98 [0.07 ; 12.73 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020 2 0% 1,444 low not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
KEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58]
1.95 [0.20 ; 19.31 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020 2 0% 1,444 low not evaluable Increase AST TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.91 [0.57; 6.42]
1.91 [0.57 ; 6.42 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.90 [0.17; 21.02]
KEYNOTE-355 (all population), 2020 1.29 [0.67; 2.48]
1.32 [0.70 ; 2.49 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020 2 0% 1,444 low not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.09 [0.01; 1.71]
KEYNOTE-355 (all population), 2020 0.83 [0.58; 1.19]
0.46 [0.07 ; 3.09 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020 2 53% 1,444 low not evaluable Maculopapular rash TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
1.89 [0.06 ; 56.64 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
0.47 [0.02 ; 14.11 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 5.72 [0.29; 114.60]
5.72 [0.29 ; 114.60 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
KEYNOTE-355 (all population), 2020 1.13 [0.34; 3.69]
1.03 [0.33 ; 3.14 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020 2 0% 1,444 low not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78]
0.94 [0.02 ; 47.78 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.01 [0.00; 0.12]
KEYNOTE-355 (all population), 2020 0.99 [0.73; 1.36]
0.11 [0.00 ; 12.49 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020 2 91% 1,444 low not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.13 [0.02; 1.08]
0.13 [0.02 ; 1.08 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Pancytopenia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.24 [0.01; 5.23]
0.24 [0.01 ; 5.23 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.16 [0.01; 3.13]
0.16 [0.01 ; 3.13 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Pneumonia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.24 [0.01; 5.23]
0.24 [0.01 ; 5.23 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 5.72 [0.29; 114.60]
KEYNOTE-355 (all population), 2020 6.05 [0.34; 108.78]
5.89 [0.74 ; 47.15 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020 2 0% 1,444 low not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
1.89 [0.06 ; 56.64 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18]
0.94 [0.06 ; 15.18 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Sepsis TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78]
0.94 [0.02 ; 47.78 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.90 [0.17; 21.02]
KEYNOTE-355 (all population), 2020 10.16 [0.59; 174.64]
3.82 [0.61 ; 23.97 ] KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020 2 0% 1,444 moderate not evaluable Stomatitis TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11]
0.47 [0.02 ; 14.11 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18]
0.94 [0.06 ; 15.18 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78]
0.94 [0.02 ; 47.78 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Urticaria TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64]
1.89 [0.06 ; 56.64 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-119 (all population), 2019 0.47 [0.04; 5.22]
0.47 [0.04 ; 5.22 ] KEYNOTE-119 (all population), 2019 1 0% 601 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-01 23:06 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 324,142,305,306,98,96,269,60,143,270,140,240
- treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561